Nicox SA (OTCMKTS:NICXF – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Nicox in a report released on Wednesday, September 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.06) for the year, up from their prior forecast of ($0.08). The consensus estimate for Nicox’s current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Nicox’s FY2027 earnings at $0.02 EPS.
Nicox Price Performance
Nicox stock opened at $0.30 on Friday. The company’s 50 day simple moving average is $0.30 and its 200 day simple moving average is $0.30. Nicox has a fifty-two week low of $0.25 and a fifty-two week high of $0.30.
About Nicox
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
Recommended Stories
- Five stocks we like better than Nicox
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
